Cardio Diagnostics director granted 2,306 stock options
Cardio Diagnostics Holdings, Inc. director Peter K. Fung reported receiving a grant of stock options.
Rhea-AI Filing Summary
Cardio Diagnostics Holdings, Inc. director Peter K. Fung reported receiving a grant of stock options. On 12/31/2025, he was awarded options to buy 2,306 shares of common stock at an exercise price of $2.71 per share. After this grant, he beneficially owns a total of 6,308 stock options directly. This filing records the equity compensation awarded to a board member and does not involve any sale of shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 2,306 | $2.71 | $6K |
FAQ
What insider transaction did CDIO director Peter K. Fung report?
Peter K. Fung, a director of Cardio Diagnostics Holdings, Inc. (CDIO), reported the grant of stock options as an equity award.
How many stock options were granted to the CDIO director?
He was granted 2,306 stock options, each representing the right to buy one share of Cardio Diagnostics common stock.
What is the exercise price of the new Cardio Diagnostics stock options?
The granted stock options have an exercise price of $2.71 per share.
What is the total number of stock options Peter K. Fung owns after this transaction?
Following this grant, Peter K. Fung beneficially owns 6,308 stock options directly.
Is the ownership of these Cardio Diagnostics options direct or indirect?
The filing shows direct ownership of the 6,308 stock options, with no indirect ownership entity disclosed.
AI-generated analysis. How Rhea-AI works. Not financial advice.